早期给予参附注射液对脓毒症患者血流动力学的影响:多中心随机对照试验
该研究为前瞻性多中心随机对照试验,纳入中国中部4家三级医院ICU中18-75岁符合Sepsis-3诊断标准的脓毒症患者172例,随机分为参附注射液组和对照组各86例,在脓毒症诊断后5小时内以20 mL/hr速率输注参附注射液或生理盐水,每日2次,连续3天。主要终点血管加压药用量(去甲肾上腺素等效剂量)两组无显著差异(22.00 [16.00-29.50] vs. 20.00 [12.50-28.50],p=0.16)。次要终点显示参附注射液组ICU死亡率(3.5% vs. 11.6%,p=0.04)和28天死亡率(15.1% vs. 27.9%,p=0.04)显著降低,舌下微循环指标显著改善,两组均未观察到药物相关不良事件。作者结论认为早期给予参附注射液未减少血管加压药用量,次要结局提示可能降低死亡率和改善微循环,需进一步验证。
要点
- 脓毒症诊断后5小时内开始参附注射液20 mL/hr输注、每日2次连续3天,未显著减少去甲肾上腺素等效剂量(22.00 [16.00-29.50] vs. 20.00 [12.50-28.50],p=0.16)。
- 参附注射液组ICU死亡率3.5% vs. 对照组11.6%(p=0.04),28天死亡率15.1% vs. 27.9%(p=0.04),均为次要终点。
- 参附注射液组舌下微循环指标较对照组显著改善,两组均未观察到药物相关不良事件。
- 作者结论:早期给予参附注射液未减少血管加压药用量,死亡率和微循环改善为次要结局提示,需进一步验证。
适用人群与场景
- 中国中部4家三级医院ICU中18-75岁、符合Sepsis-3诊断标准的脓毒症患者。
诊断标准与关键阈值
- 纳入标准:符合Sepsis-3诊断标准。
处置流程与药物剂量
- 参附注射液组:从脓毒症诊断时起,以20 mL/hr速率输注参附注射液5小时,每日2次,连续3天。
- 对照组:从脓毒症诊断时起,以20 mL/hr速率输注生理盐水5小时,每日2次,连续3天。
研究设计与关键结果
- 研究类型:前瞻性、多中心随机对照试验,4家三级医院,纳入172例(参附注射液组86例,对照组86例)。
- 主要终点:血管加压药用量(去甲肾上腺素等效剂量)参附注射液组22.00 [16.00-29.50] vs. 对照组20.00 [12.50-28.50],p=0.16,无显著改善。
- 次要终点:ICU死亡率参附注射液组3.5% vs. 对照组11.6%(p=0.04);28天死亡率15.1% vs. 27.9%(p=0.04)。
- 次要终点:参附注射液组舌下微循环指标较对照组显著改善。
- 不良事件:两组均未观察到药物相关不良事件。
证据类型、等级与局限
- 证据类型:前瞻性、多中心随机对照试验。
- 局限:作者结论指出死亡率和微循环改善为次要结局提示,需进一步验证。
对床旁实践的改变
- 作者结论认为早期给予参附注射液未减少血管加压药用量,次要结局提示可能降低死亡率和改善微循环,需进一步验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the effect of early administration of Shenfu injection (SFI) on hemodynamics and clinical outcomes in ICU patients with sepsis.
DESIGN: Prospective, multicenter randomized controlled trial.
SETTING: Four tertiary care hospitals located in central China.
PATIENTS: ICU patients 18-75 years old who met the Sepsis-3 diagnostic criteria.
INTERVENTIONS: Eligible septic patients were randomized to the SFI group or the control group, receiving either SFI or normal saline at a rate of 20 mL/hr in 5 hours from the time of sepsis diagnosis, bid for 3 consecutive days.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was the amount of vasopressors administration (calculated as the norepinephrine equivalents [NEEs]). A total of 172 patients were enrolled, with 86 assigned to the SFI group and 86 to the control group. Compared with the control group, the SFI group had no significant improvement in total NEE doses (22.00 [16.00-29.50] vs. 20.00 [12.50-28.50]; p = 0.16). However, compared with the control group, the SFI group showed significantly lower mortality both during ICU stay (3.5% vs. 11.6%; p = 0.04) and 28 days after treatment (15.1% vs. 27.9%; p = 0.04). The SFI group also exhibited a significant improvement in sublingual microcirculation indicators compared with control group. No significant drug-related adverse events were noted in either group.
CONCLUSIONS: The early administration of SFI did not decrease the dosage of vasopressors. The secondary outcomes suggested a potential decrease in mortality and possible improvement in microcirculation, findings that require further validation.
参考来源
- Xiong Y, Zhang D, Dong H, et al. Effect of Early Administration of Shenfu Injection on Hemodynamics in Septic Patients: A Multicenter, Randomized, Controlled Trial. Crit Care Med. 2026. PMID: 42456111. doi:10.1097/CCM.0000000000007269
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。